Pfizer (PFE) Accounts Payables (2009 - 2026)

Pfizer (PFE) has 18 years of Accounts Payables data on file, last reported at $4.5 billion in Q1 2026.

• Accounts Payables for Q1 2026 came in at $4.5 billion, down 14.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.5 billion (down 14.01% YoY), and the FY2025 annual result was $5.2 billion, down 6.98% from the prior year.
• Accounts Payables eased to $4.5 billion in Q1 2026 per PFE's latest filing, from $5.2 billion in the prior quarter.
• Over five years, Accounts Payables peaked at $6.8 billion in Q4 2022 and troughed at $4.5 billion in Q1 2026.
• A 5-year average of $5.6 billion and a median of $5.5 billion in 2022 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2024: Accounts Payables surged 43.47% in 2022, then declined 16.05% in 2024.
• A 5-year view of Accounts Payables shows it stood at $6.8 billion in 2022, then slipped by 1.45% to $6.7 billion in 2023, then decreased by 16.05% to $5.6 billion in 2024, then slipped by 6.98% to $5.2 billion in 2025, then decreased by 14.01% to $4.5 billion in 2026.
• Business Quant data shows PFE's Accounts Payables at $4.5 billion in Q1 2026, $5.2 billion in Q4 2025, and $5.0 billion in Q3 2025.